{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:20:55Z","timestamp":1763018455771,"version":"3.37.3"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T00:00:00Z","timestamp":1634083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T00:00:00Z","timestamp":1634083200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100007655","name":"Aichi Cancer Research Foundation","doi-asserted-by":"publisher","award":["2021-1-9"],"award-info":[{"award-number":["2021-1-9"]}],"id":[{"id":"10.13039\/501100007655","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["19ek0510023h0003"],"award-info":[{"award-number":["19ek0510023h0003"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1038\/s41409-021-01501-9","type":"journal-article","created":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T18:17:08Z","timestamp":1634149028000},"page":"78-82","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Autologous hematopoietic cell transplantation during second or subsequent complete remission of acute promyelocytic leukemia: a prognostic factor analysis"],"prefix":"10.1038","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1602-9775","authenticated-orcid":false,"given":"Masamitsu","family":"Yanada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3631-244X","authenticated-orcid":false,"given":"Shuichi","family":"Ota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Mukae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miho","family":"Nara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2635-3395","authenticated-orcid":false,"given":"Shinichi","family":"Kako","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akinori","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5952-5926","authenticated-orcid":false,"given":"Naoyuki","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Sawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuaki","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3864-0823","authenticated-orcid":false,"given":"Makoto","family":"Onizuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4866-9307","authenticated-orcid":false,"given":"Yoshinobu","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuo","family":"Ichinohe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4404-2870","authenticated-orcid":false,"given":"Yoshiko","family":"Atsuta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shingo","family":"Yano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,13]]},"reference":[{"key":"1501_CR1","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1182\/blood-2019-01-894980","volume":"133","author":"MA Sanz","year":"2019","unstructured":"Sanz MA, Fenaux P, Tallman MS, Estey EH, Lowenberg B, Naoe T, et al. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood 2019;133:1630\u201343.","journal-title":"Blood"},{"key":"1501_CR2","doi-asserted-by":"publisher","first-page":"614215","DOI":"10.3389\/fonc.2021.614215","volume":"11","author":"J Sanz","year":"2021","unstructured":"Sanz J, Montesinos P, Sanz MA. Role of hematopoietic stem cell transplantation in acute promyelocytic leukemia. Front Oncol. 2021;11:614215.","journal-title":"Front Oncol"},{"key":"1501_CR3","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s12185-019-02759-y","volume":"111","author":"M Yanada","year":"2020","unstructured":"Yanada M, Takami A, Mizuno S, Mori J, Chou T, Usuki K, et al. Autologous hematopoietic cell transplantation for acute myeloid leukemia in adults: 25 years of experience in Japan. Int J Hematol. 2020;111:93\u2013102.","journal-title":"Int J Hematol"},{"key":"1501_CR4","doi-asserted-by":"publisher","first-page":"3852","DOI":"10.1200\/JCO.2001.19.18.3852","volume":"19","author":"SL Soignet","year":"2001","unstructured":"Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 2001;19:3852\u201360.","journal-title":"J Clin Oncol"},{"key":"1501_CR5","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1182\/blood-2012-11-466862","volume":"121","author":"M Yanada","year":"2013","unstructured":"Yanada M, Tsuzuki M, Fujita H, Fujimaki K, Fujisawa S, Sunami K, et al. Phase 2 study of arsenic trioxide followed by autologous hematopoietic cell transplantation for relapsed acute promyelocytic leukemia. Blood 2013;121:3095\u2013102.","journal-title":"Blood"},{"key":"1501_CR6","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1038\/leu.2015.12","volume":"29","author":"E Lengfelder","year":"2015","unstructured":"Lengfelder E, Lo-Coco F, Ades L, Montesinos P, Grimwade D, Kishore B, et al. Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet. Leukemia 2015;29:1084\u201391.","journal-title":"Leukemia"},{"key":"1501_CR7","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1016\/j.bbmt.2009.07.010","volume":"15","author":"R Thirugnanam","year":"2009","unstructured":"Thirugnanam R, George B, Chendamarai E, Lakshmi KM, Balasubramanian P, Viswabandya A, et al. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen. Biol Blood Marrow Transpl. 2009;15:1479\u201384.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1501_CR8","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/bmt.2016.96","volume":"51","author":"C Ganzel","year":"2016","unstructured":"Ganzel C, Mathews V, Alimoghaddam K, Ghavamzadeh A, Kuk D, Devlin S, et al. Autologous transplant remains the preferred therapy for relapsed APL in CR2. Bone Marrow Transpl. 2016;51:1180\u20133.","journal-title":"Bone Marrow Transpl"},{"key":"1501_CR9","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1111\/bjh.17221","volume":"192","author":"NA Fouzia","year":"2021","unstructured":"Fouzia NA, Sharma V, Ganesan S, Palani HK, Balasundaram N, David S, et al. Management of relapse in acute promyelocytic leukaemia treated with up-front arsenic trioxide-based regimens. Br J Haematol. 2021;192:292\u201399.","journal-title":"Br J Haematol"},{"key":"1501_CR10","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1200\/JCO.2005.03.127","volume":"23","author":"S de Botton","year":"2005","unstructured":"de Botton S, Fawaz A, Chevret S, Dombret H, Thomas X, Sanz M, et al. Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: a retrospective analysis of the European acute promyelocytic leukemia group. J Clin Oncol. 2005;23:120\u20136.","journal-title":"J Clin Oncol"},{"key":"1501_CR11","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.bbmt.2014.03.025","volume":"20","author":"JL Holter Chakrabarty","year":"2014","unstructured":"Holter Chakrabarty JL, Rubinger M, Le-Rademacher J, Wang HL, Grigg A, Selby GB, et al. Autologous is superior to allogeneic hematopoietic cell transplantation for acute promyelocytic leukemia in second complete remission. Biol Blood Marrow Transpl. 2014;20:1021\u20135.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1501_CR12","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1080\/10428194.2016.1231406","volume":"58","author":"M Yanada","year":"2017","unstructured":"Yanada M, Yano S, Kanamori H, Gotoh M, Emi N, Watakabe K, et al. Autologous hematopoietic cell transplantation for acute promyelocytic leukemia in second complete remission: outcomes before and after the introduction of arsenic trioxide. Leuk Lymphoma. 2017;58:1061\u201367.","journal-title":"Leuk Lymphoma"},{"key":"1501_CR13","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1038\/s41409-020-01162-0","volume":"56","author":"J Sanz","year":"2021","unstructured":"Sanz J, Labopin M, Sanz MA, Aljurf M, Sousa AB, Craddock C, et al. Hematopoietic stem cell transplantation for adults with relapsed acute promyelocytic leukemia in second complete remission. Bone Marrow Transpl. 2021;56:1272\u201380.","journal-title":"Bone Marrow Transpl"},{"key":"1501_CR14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12185-015-1894-x","volume":"103","author":"Y Atsuta","year":"2016","unstructured":"Atsuta Y. Introduction of transplant registry unified management program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data). Int J Hematol. 2016;103:3\u201310.","journal-title":"Int J Hematol"},{"key":"1501_CR15","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H Dohner","year":"2017","unstructured":"Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 2017;129:424\u201347.","journal-title":"Blood"},{"key":"1501_CR16","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457\u201381.","journal-title":"J Am Stat Assoc"},{"key":"1501_CR17","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"DR Cox","year":"1972","unstructured":"Cox DR. Regression models and life-tables. J R Stat Soc B 1972;34:187\u2013220.","journal-title":"J R Stat Soc B"},{"key":"1501_CR18","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","volume":"18","author":"TA Gooley","year":"1999","unstructured":"Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695\u2013706.","journal-title":"Stat Med"},{"key":"1501_CR19","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496\u2013509.","journal-title":"J Am Stat Assoc"},{"key":"1501_CR20","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1182\/blood.V90.3.1321","volume":"90","author":"G Meloni","year":"1997","unstructured":"Meloni G, Diverio D, Vignetti M, Avvisati G, Capria S, Petti MC, et al. Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML\/RAR alpha fusion gene. Blood 1997;90:1321\u20135.","journal-title":"Blood"},{"key":"1501_CR21","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1300874","volume":"369","author":"F Lo-Coco","year":"2013","unstructured":"Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N. Engl J Med. 2013;369:111\u201321.","journal-title":"N. Engl J Med"},{"key":"1501_CR22","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/S1470-2045(15)00193-X","volume":"16","author":"AK Burnett","year":"2015","unstructured":"Burnett AK, Russell NH, Hills RK, Bowen D, Kell J, Knapper S, et al. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2015;16:1295\u2013305.","journal-title":"Lancet Oncol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-021-01501-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-021-01501-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-021-01501-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T22:19:00Z","timestamp":1725920340000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-021-01501-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,13]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["1501"],"URL":"https:\/\/doi.org\/10.1038\/s41409-021-01501-9","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"type":"print","value":"0268-3369"},{"type":"electronic","value":"1476-5365"}],"subject":[],"published":{"date-parts":[[2021,10,13]]},"assertion":[{"value":"7 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}